MYD88 L265P present in ~70-90% of PCNSL (often co-mutated with CD79B). Ibrutinib monother...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-MYD88-L265P-PCNSL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PCNSL |
| Sources | SRC-CIVIC SRC-NCCN-CNS-2025 |
Actionability Facts
| Biomarker | BIO-MYD88-L265P |
|---|---|
| Variant | L265P |
| Disease | DIS-PCNSL |
| ESCAT tier | IIB |
| Recommended combinations | ibrutinib (R/R PCNSL, off-label NCCN-supported), ibrutinib + HD-MTX-based regimens (trial), MTX-based induction → consolidation per usual PCNSL algorithm |
| Evidence summary | MYD88 L265P present in ~70-90% of PCNSL (often co-mutated with CD79B). Ibrutinib monotherapy crosses BBB and shows activity in R/R PCNSL (Grommes et al. Cancer Discov 2017; Soussain Eur J Cancer 2019). Off-label NCCN-supported in R/R disease. |
Notes
ESCAT IIB. PCNSL biology overlaps MCD-DLBCL.
Used By
No reverse references found in the YAML corpus.